**6. Conclusion**

The HAART has as one of its major collateral effect the lipodystrophy syndrome. There is necessity of more studies to deep into physiopathology of this syndrome; and metabolic and cardiovascular complications secondary to HAART. Dyslipidemia stands out as one of the most prevalent metabolic changes in patients with HIV, what makes it essential to feasibility of research in therapeutic care to clarifying of the clinical management. It is noted that nutritional guideline and/or hypolipidemic use, when have there been acceptance to treatment, takes place improvements of the lipid profile, can also there be normalization of those levels, in particular of the triglyceride levels. However, the adherence neither always takes place, what difficult the management of those patients.
